ABBV Jun 2024 160.000 put
| Previous close | 23.50 |
| Open | 23.50 |
| Bid | 18.45 |
| Ask | 19.55 |
| Strike | 160.00 |
| Expiry date | 2024-06-21 |
| Day's range | 23.50 - 23.50 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Zacks
Here's What's Driving AbbVie's (ABBV) Outperformance This Year
AbbVie (ABBV) boasts several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.
- Motley Fool
8 Dividend Aristocrats to Buy Now for a Lifetime of Passive Income
There is no one-size-fits-all strategy that has the potential to make investors wealthy over time, but there are few approaches that have a better track record of success than investing in dividend stocks. Companies that pay dividends are often successful, profitable businesses -- year in, year out -- which have generally proven over time that they can withstand market cycles and recessions. The asset managers at Hartford Financial Services looked at the performance of the benchmark S&P 500 going all the way back to 1930 and found there was not a single decade in which dividend stocks in the index didn't generate positive returns, even when the broader market was losing money for investors.
- Motley Fool
Better Dividend Stock: AbbVie or Viatris?
AbbVie (NYSE: ABBV) and Viatris (NASDAQ: VTRS) have a lot more in common than first glances would suggest. The two were both spun off from larger companies and now deliver above-average dividend yields. In AbbVie's case, it is the patent cliff next year for its immunology drug Humira, the top-selling drug last year other than COVID-19 vaccines.
